Thymalin

✓Key benefits

📈What to expect

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

Thymalin is a mixture of short peptides isolated from bovine thymus tissue, developed by the Khavinson group at the Saint Petersburg Institute of Bioregulation and Gerontology. It has been registered as a pharmaceutical product in Russia since 1982 and is prescribed for immunodeficiency, chronic infections, and immune recovery after radiation or chemotherapy. In a remarkable 15-year clinical trial (2001-2016), Khavinson reported that elderly patients given thymalin and epithalamin showed a 28% reduction in mortality compared to controls. Thymalin should not be confused with thymulin (a single zinc-dependent nonapeptide) or thymosin alpha-1 (Zadaxin) - these are three distinct thymic peptide products.

⚙️How it works

As a polypeptide complex, thymalin contains multiple short peptides that collectively modulate thymic function. The proposed mechanism involves restoration of T-cell differentiation pathways in the involuted thymus, upregulation of T-cell receptor diversity, normalisation of the CD4/CD8 ratio, and enhancement of NK cell cytotoxicity. Khavinson's peptide bioregulation theory suggests these short peptides interact with DNA regulatory regions to influence gene expression in immunocompetent cells, restoring age-declined immune function at the epigenetic level.

⚡Side effects

📅Research history

The Khavinson longevity trial

Between 2001 and 2016, Khavinson conducted a clinical study on elderly patients (60-80 years) in Saint Petersburg. Participants received annual courses of thymalin (thymus bioregulator) and epithalamin (pineal bioregulator). After 15 years, the treatment group showed a 28% reduction in all-cause mortality compared to age-matched controls. Cardiovascular mortality, infection rates, and cancer incidence were all lower in the treatment group. While this study has been criticised for methodological limitations (not double-blinded, potential selection bias), it remains the longest published dataset on peptide bioregulator effects on human longevity.

Thymalin vs thymulin vs thymosin alpha-1

These three thymic peptides are frequently confused. Thymalin is a polypeptide complex (mixture) extracted from bovine thymus - available as a pharmaceutical in Russia. Thymulin (FTS) is a single nine-amino-acid peptide that requires zinc as a cofactor. Thymosin alpha-1 (Zadaxin) is a 28-amino-acid synthetic peptide approved in over 30 countries for hepatitis B. Each has different mechanisms, dosing, and evidence bases. Thymalin is the least characterised at the molecular level but has the longest clinical use history.

References

1. [1]Khavinson VK. 'Peptides and ageing.' Neuroendocrinology Letters, 2002.
2. [2]Khavinson VK, et al. 'Effect of peptide bioregulators on mortality in elderly patients: 15-year follow-up.' Bulletin of Experimental Biology and Medicine, 2016.

Frequently asked questions

Related peptides